Heart failure treatment outcomes study
Part of Heart & circulation clinical trials.
This study looks at how well patients with heart failure and a weakened heart muscle (ejection fraction of 40% or lower) do when taking the recommended heart failure medications. The goal is to see if these treatments improve their heart function and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a diagnosis of heart failure with reduced ejection fraction (a weakened heart's pumping ability) of 40% or less, confirmed by an echocardiogram (ultrasound of the heart).
- You should be stable on (or about to start) the standard heart failure medications your doctor prescribes.
- You should not be in the hospital for severe heart failure needing IV medications right now.
- You should not have advanced kidney disease (on dialysis or with very poor kidney function) or severe heart valve problems that need urgent surgery.
- If you have another serious illness that might limit your life to less than 6 months, you may not be eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study evaluates how well doctors follow guidelines for treating heart failure with reduced ejection fraction (HFrEF). It aims to improve the quality of care you receive during your regular clinic visits over the next year.
This study tests tools to help doctors and patients work together to start or adjust heart failure medicines. You may qualify if your heart's pumping strength is low and you are missing certain recommended medications.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This study looks at what helps people with heart failure get the most out of a cardiac rehab program. It aims to find out which patients improve the most after completing phase II cardiac rehab.
This study looks at how well patients with heart failure who have reduced pumping function do when they receive the standard recommended medications. It aims to see short-term improvements in heart function and symptoms.
This study tests a new drug called finerenone to see if it can improve heart function in people with a type of heart failure where the heart pumps normally but is stiff. It may help reduce symptoms and improve quality of life.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.